FABP4 Antibody [H23L13] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat

Lane 1: Mouse brown adipose, Lane 2: Rat brown adipose

Usage Information

Dilution
WB1:1000

Application
WB

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
15 kDa

Datasheet & SDS

Biological Description

Specificity
FABP4 Antibody [H23L13] detects endogenous levels of total FABP4 protein.

Clone
H23L13

Synonym(s)
Fatty acid-binding protein, adipocyte;Adipocyte lipid-binding protein (ALBP);Adipocyte-type fatty acid-binding protein (A-FABP; AFABP);Fatty acid-binding protein 4;FABP4

Background
Fatty acid–binding protein 4 (FABP4), also known as adipocyte fatty acid–binding protein (A‑FABP or aP2), is a small cytoplasmic lipid chaperone of the FABP family that is predominantly expressed in adipocytes and macrophages and functions as a major intracellular carrier of long‑chain fatty acids and other hydrophobic ligands. The protein binds fatty acids with high affinity, shuttles them between membranes and enzymes, and modulates the availability of lipid species for metabolic, signaling, and inflammatory pathways, including lipolysis‑driven release, β‑oxidation, and eicosanoid production. FABP4 influences PPARγ activity and adipogenic gene programs, and in macrophages it contributes to lipid‑handling and proinflammatory activation, thereby linking lipid trafficking to both metabolic regulation and low‑grade inflammation (“metaflammation”). Mouse models lacking FABP4 show increased obesity on high‑fat diets yet remain protected from insulin resistance and diabetes, and FABP4‑deficient mice also exhibit reduced atherosclerosis when crossed with ApoE‑null backgrounds, indicating that FABP4 couples obesity to insulin resistance and vascular disease. Low‑expression variant in the FABP4 promoter associates with reduced risk of type 2 diabetes and coronary heart disease, and circulating FABP4 levels correlate with insulin resistance, metabolic syndrome, and cardiovascular events, acting as a systemic biomarker and effector.

Background

Fatty acid–binding protein 4 (FABP4), also known as adipocyte fatty acid–binding protein (A‑FABP or aP2), is a small cytoplasmic lipid chaperone of the FABP family that is predominantly expressed in adipocytes and macrophages and functions as a major intracellular carrier of long‑chain fatty acids and other hydrophobic ligands. The protein binds fatty acids with high affinity, shuttles them between membranes and enzymes, and modulates the availability of lipid species for metabolic, signaling, and inflammatory pathways, including lipolysis‑driven release, β‑oxidation, and eicosanoid production. FABP4 influences PPARγ activity and adipogenic gene programs, and in macrophages it contributes to lipid‑handling and proinflammatory activation, thereby linking lipid trafficking to both metabolic regulation and low‑grade inflammation (“metaflammation”). Mouse models lacking FABP4 show increased obesity on high‑fat diets yet remain protected from insulin resistance and diabetes, and FABP4‑deficient mice also exhibit reduced atherosclerosis when crossed with ApoE‑null backgrounds, indicating that FABP4 couples obesity to insulin resistance and vascular disease. Low‑expression variant in the FABP4 promoter associates with reduced risk of type 2 diabetes and coronary heart disease, and circulating FABP4 levels correlate with insulin resistance, metabolic syndrome, and cardiovascular events, acting as a systemic biomarker and effector.

References
https://pubmed.ncbi.nlm.nih.gov/30726793/ https://pubmed.ncbi.nlm.nih.gov/34244239/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%